undamentalytics Newsletter
Sign in

Sagimet Biosciences Inc. (SGMT) stock

Add to watchlist

Add holding +

NASDAQ: SGMT Nasdaq Biotechnology Next results ~November 12, 2026

Sagimet Biosciences Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 5 selling0 purchases and 10 sales by directors and officers, last 12 monthsInsider trades
  • Funds92 adding, 34 cuttingOf 32 active managers that changed their stake, 20 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Sagimet Biosciences Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 11 November; the share price can move sharply on the day.
  • Volatile shares. Over the past year the shares showed annualised volatility of 82% and a beta of 2.0 against the S&P 500.
  • Heavily shorted. 16.5% of the shares available to trade are sold short (7.5 days of average volume to cover).

Latest results

Earnings per share
-$0.26 against an average estimate of -$0.27: beat by 2.1%
Share reaction
-1.9% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500
Next report
November 12, 2026; average EPS estimate -$0.26

Sagimet Biosciences' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-2.3%
  • 1 week+1.4%
  • 1 month+6.0%
  • This year+63.7%
  • 1 year+13.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 11, 2026
Next results (est.)
November 11, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Agreement
  3. Announcement
  4. Insider trade
  5. Announcement
  6. Results
  7. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Sagimet Biosciences Inc. valuation models and calculator

No model value for Sagimet Biosciences Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, before the open. Analysts expect revenue of $0 and EPS of −$0.26 (range −$0.34 to −$0.20) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.12 +29% — 0%
Next −$1.30 −16% $8m 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −8.3% on 90 days ago. In the last 30 days, 4 analysts raised Sagimet Biosciences Inc.'s forecast and 0 cut it.

Consensus EPS forecast Sagimet Biosciences Inc., last 90 days
−$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.22 Current fiscal year, 60 days ago: −$1.20 Current fiscal year, 30 days ago: −$1.16 Current fiscal year, 7 days ago: −$1.12 Current fiscal year, Now: −$1.12 −$1.12 Next fiscal year, 90 days ago: −$1.31 Next fiscal year, 60 days ago: −$1.34 Next fiscal year, 30 days ago: −$1.37 Next fiscal year, 7 days ago: −$1.30 Next fiscal year, Now: −$1.30 −$1.30

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.22−$1.31
60 days ago −$1.20−$1.34
30 days ago −$1.16−$1.37
7 days ago −$1.12−$1.30
Now −$1.12−$1.30

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.27 −$0.26 +2.1%
Mar 2026 −$0.35 −$0.33 +5.0%
Dec 2025 −$0.40 −$0.29 +27.8%
Sept 2025 −$0.39 −$0.40 −2.2%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

12 analysts, Oct 2026
Buy1192%
Hold00%
Sell18%

Monthly trend

  1. Oct 202629112
  2. Sep 202629112
  3. Aug 202618110
  4. Jul 202618110

Counts of recommendations published by analysts covering Sagimet Biosciences Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
16.5%
of tradable shares
Days to cover
7.5
at average volume
Short interest, 1 month
+12%
to October 15, 2026
Held by institutions
77%
of shares
Held by insiders
3.0%
of shares
Employees
16
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Return and risk by year

Calendar year 202420252026 to date
Return
SGMT−17%+32%+64%
Industry peers (median)−29%−5%−27%
S&P 500+25%+18%+11%
Months that ended higher
SGMT33%42%46%
S&P 50075%75%46%
Largest fall from a high during the year
SGMT−87%−72%−33%
S&P 500−8%−19%−9%

Worst fall since July 14, 2023: 90% from January 22, 2024 to April 8, 2025. Getting back needed a 870% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$4.55 – $11.17
From 52-week high
−13.2%
vs 50-day average
−2.3%
vs 200-day average
+29.0%
Volatility (1 year)
82%
Beta vs S&P 500
2.00

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±11.0%
After a week
6 up, 6 down
typical move ±16.9%
After a month
4 up, 8 down
typical move ±22.6%
Results releasedNext dayS&P 500 next day5 days21 days
August 11, 2026 −1.9% −0.1% +10.6% +15.6%
May 12, 2026 −1.2% +0.4% −15.0% −16.4%
April 27, 2026 +49.3% −0.3% +34.8% +23.2%
March 11, 2026 −3.4% −1.6% −12.1% −4.2%
November 13, 2025 −12.1% −1.7% −17.6% −31.6%
August 13, 2025 −9.2% +0.4% −24.8% −29.2%
May 8, 2025 −2.4% +0.6% −0.9% +59.6%
March 12, 2025 +3.4% −0.8% +13.4% −34.3%
November 14, 2024 −21.4% −1.9% −25.2% −4.8%
August 14, 2024 +3.8% +2.0% +15.8% +39.8%
May 15, 2024 +8.4% +1.0% +16.0% −5.5%
March 25, 2024 +16.0% −0.5% +16.2% −7.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$394M
Institutions reporting
122
Shares held vs prior quarter
▲ 282.0%
Positions opened / closed
56 / 24

Top buyers and sellers, Q2 2026: 92 institutions bought and 34 sold ; the biggest buyer was Blackrock, Inc (+5.8M shares) and the biggest seller Marshall Wace, LLP (−966K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $50.8M 6.6M 12.9% ▲ 722.0%
Balyasny Asset Management L.P. $28M 3.6M 7.1% New
Woodline Partners LP $23.2M 3.0M 5.9% ▲ 199.8%
Silverarc Capital Management, LLC $22.6M 2.9M 5.7% New
Vanguard Capital Management LLC $19.8M 2.6M 5.0% ▲ 133.5%
Caligan Partners LP $19.3M 2.5M 4.9% New
Bvf Inc $19.3M 2.5M 4.9% New
Affinity Asset Advisors, LLC $19.3M 2.5M 4.9% ▲ 187.8%
Federated Hermes, Inc. $16.1M 2.1M 4.1% ▲ 267085.0%
Great Point Partners LLC $15.7M 2.0M 4.0% New
State Street Corp $15.4M 2.0M 3.9% ▲ 1449.1%
Saturn V Capital Management LP $11.4M 1.5M 2.9% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Sagimet Biosciences Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $4.9M 10 trades by 5 insiders · 86% under pre-set plans
Net ▼ $4.9M net selling
Insider Date Trade Shares Price Value
Kemble George Director August 14, 2026 Sell pre-set plan 350,987 $10.23 $3.6M
Kemble George Director August 11, 2026 Sell pre-set plan 20,206 $9.95 $201,050
Kemble George Director July 20, 2026 Sell pre-set plan 18,844 $7.46 $140,576
Rozek Elizabeth Chief Legal & Admin. Officer July 20, 2026 Sell 10,545 $7.76 $81,829
Happel David President & CEO July 20, 2026 Sell 64,051 $7.76 $497,036
Rozek Elizabeth Chief Legal & Admin. Officer February 10, 2026 Sell 2,622 $5.36 $14,054
Martins Eduardo Bruno Chief Medical Officer February 10, 2026 Sell 3,640 $5.36 $19,510
Chauche Thierry Chief Financial Officer February 10, 2026 Sell 1,312 $5.36 $7,032
Happel David President & CEO February 10, 2026 Sell 12,101 $5.36 $64,861
Kemble George Executive Chairman November 20, 2025 Sell pre-set plan 37,688 $7.69 $289,821

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 11, 2026 estimated from the company's past filing pattern, not announced

  • August 11, 2026
  • May 12, 2026
  • April 27, 2026
  • March 11, 2026
  • November 13, 2025
  • August 13, 2025

Recent SEC filings

Data status

When each part of this page on Sagimet Biosciences Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Sagimet Biosciences Inc. in brief

What does Sagimet Biosciences Inc. do?
Sagimet Biosciences Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Sagimet Biosciences Inc.'s stock ticker?
Sagimet Biosciences Inc. trades under the ticker SGMT on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Sagimet Biosciences Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Balyasny Asset Management L.P. and Woodline Partners LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Sagimet Biosciences Inc. stock?
Over the last 12 months, Sagimet Biosciences Inc.'s directors and officers reported 0 open-market purchases and 10 sales on Form 4. The insider trading page charts every trade.
When is Sagimet Biosciences Inc.'s next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Sagimet Biosciences Inc. announces its own schedule.